已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

SAT-626 Use of GLP-1R Agonists in Pediatric Patients with Type 1 Diabetes and Obesity: A Case Series

医学 1型糖尿病 血糖性 兴奋剂 内科学 相伴的 糖尿病 胰岛素 儿科 肥胖 自身抗体 内分泌学 回顾性队列研究 胰高血糖素样肽1受体 并发症 2型糖尿病 儿童肥胖 小儿内分泌
作者
Leslie Saba,Kaitlin N. Leopold,Aida Nadim Lteif,Alaa Al Nofal
出处
期刊:Journal of the Endocrine Society [Endocrine Society]
卷期号:9 (Supplement_1)
标识
DOI:10.1210/jendso/bvaf149.1152
摘要

Abstract Disclosure: L. Saba: None. K. Leopold: None. A.N. Lteif: None. A. Al Nofal: None. Objectives: Glucagon-like peptide-1 receptor (GLP-1R) agonists are currently approved for the treatment of type 2 diabetes and obesity in patients aged ≥10 and ≥12 years, respectively. While studies in adults with type 1 diabetes mellitus (T1DM) suggest potential glycemic benefits of GLP-1R agonists, data on their role in pediatric patients with T1DM and concomitant obesity remains limited. This case series evaluates the safety and efficacy of GLP-1R agonists as an adjunct to insulin therapy in pediatric patients with T1DM and obesity. Methods: A single-center retrospective review examined pediatric patients with T1DM and obesity who initiated GLP-1R agonists at <18 years of age. Data were collected from chart review and analyzed from 120 days prior to GLP-1R agonist initiation until medication discontinuation, transfer of care, or January 1, 2025. Results: 5 patients (aged 12-17 years, 4 female) with T1DM and obesity all received the GLP-1R agonist semaglutide at a mean of 5.2 years post-T1DM diagnosis. 3 patients had ≥2 positive T1DM autoantibodies, 1 had positive ZnT8 antibodies only, and 1 lacked autoantibody testing. All patients were receiving insulin therapy; 4 were utilizing insulin pumps. The overall treatment duration ranged from 194-437 days (mean: 9 months), with 3 patients experiencing interruptions (42-187 days) due to insurance or supply issues. Pre- and during-treatment data were compared with a mean interval of 140 days between GLP-1R agonist start date and comparison time point (range: 69-226 days). All patients showed reductions in glucose management indicator or hemoglobin A1c by an average of 1.2%. 3 of 4 patients with available data had decreased weight-adjusted total daily insulin requirements by 30-33% (absolute dose reduction of 0.1-0.3 units/kg/day), while 1 patient had no change. Time in range increased in all 5 patients by an average of 14.2%. The average BMI change was -9%. Adverse effects included nausea, vomiting, and abdominal pain in patient 1 leading to GLP-1R agonist discontinuation; this patient also experienced 4 episodes of diabetic ketoacidosis during treatment. Increased hypoglycemia frequency was observed in patients 2, 3, and 4, however, none required glucagon administration. To mitigate hypoglycemia risk, pump settings were proactively adjusted in patients 1 and 4. Conclusions: Beyond promoting weight loss, GLP-1R agonists show promise as an adjunctive therapy in pediatric patients with T1DM and obesity by improving glycemic control and reducing insulin requirements. The observed reduction in insulin requirements per body weight suggests an underlying degree of insulin resistance in these patients. Preemptive decrease in insulin doses with each increase in GLP-1R agonist dose should be considered to mitigate hypoglycemia risk. Larger studies are needed to assess long-term safety and efficacy in the pediatric population with T1DM and obesity. Presentation: Saturday, July 12, 2025
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
3921337477的应助被u575067采纳,获得60
刚刚
alex的应助被洋芋二号采纳,获得10
刚刚
xxx完成签到 ,获得积分10
1秒前
无花果的应助被qq采纳,获得10
1秒前
阳阳杜完成签到 ,获得积分10
2秒前
yyyyy发布了新的文献求助30
3秒前
创伤章鱼发布了新的文献求助10
3秒前
无奈板栗完成签到,获得积分20
5秒前
cbh完成签到,获得积分10
5秒前
6秒前
芦苇红柳完成签到 ,获得积分10
9秒前
漆漆完成签到 ,获得积分10
9秒前
10秒前
11秒前
科研通AI65的应助被DW采纳,获得10
12秒前
12秒前
无奈板栗发布了新的文献求助10
13秒前
yy完成签到,获得积分10
13秒前
qq发布了新的文献求助10
14秒前
研友_VZG7GZ的应助被科研通管家采纳,获得10
14秒前
学霸业的应助被科研通管家采纳,获得10
14秒前
Owen的应助被科研通管家采纳,获得10
15秒前
15秒前
情怀的应助被科研通管家采纳,获得10
15秒前
科研通AI65的应助被科研通管家采纳,获得10
15秒前
u575067发布了新的文献求助60
15秒前
Maestro_S的应助被科研通管家采纳,获得10
15秒前
Akim的应助被科研通管家采纳,获得10
15秒前
Hello的应助被3921337477采纳,获得10
16秒前
可爱的函函的应助被3921337477采纳,获得10
16秒前
molihuakai的应助被3921337477采纳,获得10
16秒前
hcg完成签到,获得积分10
16秒前
16秒前
17秒前
inferyes完成签到,获得积分10
17秒前
踏实的雁兰完成签到,获得积分10
18秒前
Elaine完成签到 ,获得积分10
19秒前
21秒前
3921337477的应助被u527218采纳,获得60
21秒前
顺利毕业完成签到,获得积分10
23秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8184867
求助须知:如何正确求助?哪些是违规求助? 9573803
关于积分的说明 21833148
捐赠科研通 7782177
什么是DOI,文献DOI怎么找? 3434414
关于科研通互助平台的介绍 2558563
邀请新用户注册赠送积分活动 2481067